Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

MedMen Enterprises

CNSX:MMEN
Snowflake Description

Slightly overvalued with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
MMEN
CNSX
CA$234M
Imp Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

MedMen Enterprises Inc., together with its subsidiaries, operates as a cannabis company in the United States. The last earnings update was 88 days ago. More info.


Add to Portfolio Compare Print
  • MedMen Enterprises has significant price volatility in the past 3 months.
MMEN Share Price and Events
7 Day Returns
9%
CNSX:MMEN
-1.8%
CA Pharmaceuticals
0.2%
CA Market
1 Year Returns
-89.6%
CNSX:MMEN
-59.2%
CA Pharmaceuticals
4.6%
CA Market
MMEN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
MedMen Enterprises (MMEN) 9% -31.5% -41.8% -89.6% - -
CA Pharmaceuticals -1.8% -13.9% -10.4% -59.2% 14.7% 327.1%
CA Market 0.2% 0.5% 4% 4.6% 7.2% 14.2%
1 Year Return vs Industry and Market
  • MMEN underperformed the Pharmaceuticals industry which returned -59.2% over the past year.
  • MMEN underperformed the Market in Canada which returned 4.6% over the past year.
Price Volatility
Industry
5yr Volatility vs Market

Value

 Is MedMen Enterprises undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of MedMen Enterprises to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for MedMen Enterprises.

CNSX:MMEN Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 7 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 11.3%
Perpetual Growth Rate 10-Year CA Government Bond Rate 1.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for CNSX:MMEN
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year CA Govt Bond Rate 1.4%
Equity Risk Premium S&P Global 5.4%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.69
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.685 (1 + (1- 21%) (282.01%))
1.812
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.81
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.44% + (1.812 * 5.44%)
11.3%

Discounted Cash Flow Calculation for CNSX:MMEN using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for MedMen Enterprises is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

CNSX:MMEN DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 11.3%)
2020 -128.38 Analyst x2 -115.35
2021 -42.11 Analyst x2 -33.99
2022 -2.00 Analyst x1 -1.45
2023 13.90 Analyst x1 9.06
2024 23.72 Est @ 70.63% 13.89
2025 35.54 Est @ 49.87% 18.70
2026 48.11 Est @ 35.34% 22.74
2027 60.22 Est @ 25.17% 25.58
2028 71.09 Est @ 18.05% 27.13
2029 80.37 Est @ 13.07% 27.56
Present value of next 10 years cash flows $-6.00
CNSX:MMEN DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $80.37 × (1 + 1.44%) ÷ (11.3% – 1.44%)
$827.28
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $827.28 ÷ (1 + 11.3%)10
$283.72
CNSX:MMEN Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $-6.00 + $283.72
$277.72
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $277.72 / 620.10
$0.45
CNSX:MMEN Discount to Share Price
Calculation Result
Exchange Rate USD/CAD
(Reporting currency to currency of CNSX:MMEN)
1.326
Value per Share
(CAD)
= Value per Share in USD x Exchange Rate (USD/CAD)
= $0.45 x 1.326
CA$0.59
Value per share (CAD) From above. CA$0.59
Current discount Discount to share price of CA$0.43
= -1 x (CA$0.43 - CA$0.59) / CA$0.59
28.4%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price MedMen Enterprises is available for.
Intrinsic value
28%
Share price is CA$0.425 vs Future cash flow value of CA$0.59393
Current Discount Checks
For MedMen Enterprises to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • MedMen Enterprises's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • MedMen Enterprises's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for MedMen Enterprises's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are MedMen Enterprises's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:MMEN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-28) in USD $-0.69
CNSX:MMEN Share Price ** CNSX (2020-02-21) in CAD CA$0.43
CNSX:MMEN Share Price converted to USD reporting currency Exchange rate (CAD/ USD) 0.754 $0.32
Canada Pharmaceuticals Industry PE Ratio Median Figure of 11 Publicly-Listed Pharmaceuticals Companies 16.05x
Canada Market PE Ratio Median Figure of 510 Publicly-Listed Companies 16.18x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of MedMen Enterprises.

CNSX:MMEN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:MMEN Share Price ÷ EPS (both in USD)

= 0.32 ÷ -0.69

-0.46x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • MedMen Enterprises is loss making, we can't compare its value to the CA Pharmaceuticals industry average.
  • MedMen Enterprises is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does MedMen Enterprises's expected growth come at a high price?
Raw Data
CNSX:MMEN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.46x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts
51.3%per year
Canada Pharmaceuticals Industry PEG Ratio Median Figure of 6 Publicly-Listed Pharmaceuticals Companies 1.55x
Canada Market PEG Ratio Median Figure of 246 Publicly-Listed Companies 1.13x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for MedMen Enterprises, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on MedMen Enterprises's assets?
Raw Data
CNSX:MMEN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-28) in USD $1.27
CNSX:MMEN Share Price * CNSX (2020-02-21) in CAD CA$0.43
CNSX:MMEN Share Price converted to USD reporting currency Exchange rate (CAD/ USD) 0.754 $0.32
Canada Pharmaceuticals Industry PB Ratio Median Figure of 154 Publicly-Listed Pharmaceuticals Companies 1.5x
Canada Market PB Ratio Median Figure of 2,342 Publicly-Listed Companies 1.4x
CNSX:MMEN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:MMEN Share Price ÷ Book Value per Share (both in USD)

= 0.32 ÷ 1.27

0.25x

* Primary Listing of MedMen Enterprises.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • MedMen Enterprises is good value based on assets compared to the CA Pharmaceuticals industry average.
X
Value checks
We assess MedMen Enterprises's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. MedMen Enterprises has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is MedMen Enterprises expected to perform in the next 1 to 3 years based on estimates from 7 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
51.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is MedMen Enterprises expected to grow at an attractive rate?
  • Unable to compare MedMen Enterprises's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare MedMen Enterprises's earnings growth to the Canada market average as it is expected to be loss making during the next 1-3 years.
  • MedMen Enterprises's revenue growth is expected to exceed the Canada market average.
Annual Growth Rates Comparison
Raw Data
CNSX:MMEN Future Growth Rates Data Sources
Data Point Source Value (per year)
CNSX:MMEN Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts 51.3%
CNSX:MMEN Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 7 Analysts 29.7%
Canada Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 69.1%
Canada Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 40.6%
Canada Market Earnings Growth Rate Market Cap Weighted Average 10.9%
Canada Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:MMEN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:MMEN Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-06-30 486 63 -12 1
2022-06-30 408 39 -39 2
2021-06-30 348 -26 -75 7
2020-06-30 219 -61 -160 7
2020-02-22
CNSX:MMEN Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-09-28 152 -230 -98
2019-06-29 130 -236 -79
2019-03-30 109 -209 -87
2018-12-29 86 -175 -81
2018-09-30 59 -113 -75
2018-06-30 40 -69 -68
2018-03-31 21 -51 -42
2017-12-31 7 -33 -28
2017-09-30 4 -22 -19
2017-06-30 3 -18 -15

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • MedMen Enterprises is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • MedMen Enterprises's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:MMEN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below

All data from MedMen Enterprises Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:MMEN Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-06-30 -0.02 -0.02 -0.02 1.00
2022-06-30 -0.07 -0.07 -0.07 1.00
2021-06-30 -0.14 -0.12 -0.16 3.00
2020-06-30 -0.31 -0.24 -0.41 3.00
2020-02-22
CNSX:MMEN Past Financials Data
Date (Data in USD Millions) EPS *
2019-09-28 -0.69
2019-06-29 -0.75
2019-03-30 -0.54
2018-12-29 -0.78
2018-09-30 -0.92
2018-06-30 -1.67
2018-03-31
2017-12-31 -0.07
2017-09-30
2017-06-30

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if MedMen Enterprises will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess MedMen Enterprises's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
MedMen Enterprises has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has MedMen Enterprises performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare MedMen Enterprises's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • MedMen Enterprises does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare MedMen Enterprises's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare MedMen Enterprises's 1-year growth to the CA Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
MedMen Enterprises's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from MedMen Enterprises Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:MMEN Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-28 152.48 -98.12 253.33
2019-06-29 129.96 -79.12 269.02
2019-03-30 108.55 -86.79 282.40
2018-12-29 86.29 -81.47 234.14
2018-09-30 59.44 -74.79 169.73
2018-06-30 39.78 -67.62 104.50
2018-03-31 20.68 -42.12 38.39
2017-12-31 7.24 -28.32 23.67
2017-09-30 4.32 -19.01 15.61
2017-06-30 2.67 -15.42 12.13

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if MedMen Enterprises has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if MedMen Enterprises has efficiently used its assets last year compared to the CA Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if MedMen Enterprises improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess MedMen Enterprises's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
MedMen Enterprises has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is MedMen Enterprises's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up MedMen Enterprises's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • MedMen Enterprises is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • MedMen Enterprises's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of MedMen Enterprises's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is not covered by short term assets, assets are 0.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from MedMen Enterprises Company Filings, last reported 4 months ago.

CNSX:MMEN Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-28 178.40 203.77 58.28
2019-06-29 200.85 187.89 46.77
2019-03-30 259.41 99.99 33.11
2018-12-29 291.70 96.41 87.72
2018-09-30 245.61 60.15 70.00
2018-06-30 195.65 55.95 79.16
2018-03-31 75.15 67.00 12.21
2017-12-31 50.59 19.34 1.65
2017-09-30 33.58 19.27 5.72
2017-06-30 33.58 19.27 5.72
  • MedMen Enterprises's level of debt (114.2%) compared to net worth is high (greater than 40%).
  • Unable to establish if MedMen Enterprises's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • MedMen Enterprises has less than a year of cash runway based on current free cash flow.
  • MedMen Enterprises has less than a year of cash runway if free cash flow continues to grow at historical rates of 94.1% each year.
X
Financial health checks
We assess MedMen Enterprises's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. MedMen Enterprises has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is MedMen Enterprises's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from MedMen Enterprises dividends.
If you bought CA$2,000 of MedMen Enterprises shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate MedMen Enterprises's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate MedMen Enterprises's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:MMEN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
North America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 11 Stocks 2.7%
Canada Market Average Dividend Yield Market Cap Weighted Average of 335 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.1%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 5.4%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

CNSX:MMEN Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-06-30
2022-06-30
2021-06-30
2020-06-30
2020-02-22

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as MedMen Enterprises has not reported any payouts.
  • Unable to verify if MedMen Enterprises's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of MedMen Enterprises's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as MedMen Enterprises has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess MedMen Enterprises's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can MedMen Enterprises afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. MedMen Enterprises has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of MedMen Enterprises's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Ryan Lissack
AGE 40
TENURE AS CEO 0 years
CEO Bio

Mr. Ryan Lissack is a Chief Executive Officer of MedMen Enterprises Inc., since 2020. He served as an Interim Chief Executive Officer of MedMen Enterprises Inc., since February 1, 2020 until 2020 and served as its Chief Technology Officer since February 25, 2019 until February 1, 2020. Mr. Lissack served as Chief Operating Officer of MedMen Enterprises Inc., until February 1, 2020. Mr. Lissack has been Chief Technology Officer at Maker Studios, Inc. since April 2012. Mr. Lissack was the Senior Director of Software Engineering at Salesforce.com.

CEO Compensation
  • Insufficient data for Ryan to compare compensation growth.
  • Insufficient data for Ryan to establish whether their remuneration is reasonable compared to companies of similar size in Canada.
Management Team Tenure

Average tenure and age of the MedMen Enterprises management team in years:

0.9
Average Tenure
37
Average Age
  • The average tenure for the MedMen Enterprises management team is less than 2 years, this suggests a new team.
Management Team

Ben Rose

TITLE
Executive Chairman
AGE
44
TENURE
0.8 yrs

Adam Bierman

TITLE
Co-Founder & Director
COMPENSATION
$7M
AGE
38

Andrew Modlin

TITLE
Co-founder
COMPENSATION
$6M
AGE
31

Ryan Lissack

TITLE
Chief Executive Officer
AGE
40

Zeeshan Hyder

TITLE
Chief Financial Officer
AGE
32
TENURE
0.3 yrs

Stéphanie Van Hassel

TITLE
Vice President of Investor Relations

Dan Edwards

TITLE
Senior Vice President of Legal Affairs

Christian Langbein

TITLE
Vice President of Communications

Esther Song

TITLE
Senior VP of Marketing & Communications
TENURE
1.1 yrs

Chris Ganan

TITLE
Chief Strategy Officer
AGE
36
TENURE
1.8 yrs
Board of Directors Tenure

Average tenure and age of the MedMen Enterprises board of directors in years:

1.8
Average Tenure
44
Average Age
  • The average tenure for the MedMen Enterprises board of directors is less than 3 years, this suggests a new board.
Board of Directors

Ben Rose

TITLE
Executive Chairman
AGE
44
TENURE
1.5 yrs

Adam Bierman

TITLE
Co-Founder & Director
COMPENSATION
$7M
AGE
38
TENURE
1.8 yrs

Andrew Modlin

TITLE
Co-founder
COMPENSATION
$6M
AGE
31
TENURE
1.8 yrs

Mark Hutchison

TITLE
Independent Director
COMPENSATION
$56K
AGE
66
TENURE
1.8 yrs

Andy Rayburn

TITLE
Independent Director
COMPENSATION
$56K
AGE
63
TENURE
1.8 yrs

Jay Brown

TITLE
Director
COMPENSATION
$56K
AGE
44
TENURE
1.6 yrs

Antonio Villaraigosa

TITLE
Director
COMPENSATION
$279K
AGE
65
TENURE
1.5 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by MedMen Enterprises individual insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
21. Jan 20 Buy Andrew Modlin Individual 16. Jan 20 16. Jan 20 1,550,387 CA$0.56 CA$869,546
21. Jan 20 Buy Adam Bierman Individual 16. Jan 20 16. Jan 20 1,550,387 CA$0.56 CA$869,546
21. Jan 20 Buy Christopher Ganan Individual 16. Jan 20 16. Jan 20 1,550,387 CA$0.56 CA$869,546
02. Oct 19 Buy Christopher Ganan Individual 30. Aug 19 06. Sep 19 265,592 CA$2.64 CA$701,986
04. Sep 19 Buy Andrew Modlin Individual 21. Aug 19 21. Aug 19 198,018 CA$2.73 CA$535,137
X
Management checks
We assess MedMen Enterprises's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. MedMen Enterprises has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

MedMen Enterprises Inc., together with its subsidiaries, operates as a cannabis company in the United States. The company cultivates, produces, and distributes, and retails recreational and medicinal cannabis under the [statemade], LuxLyte, and MedMen Red brand names. As of November 11, 2019, it operated 34 retail stores. The company was founded in 2010 and is headquartered in Culver City, California.

Details
Name: MedMen Enterprises Inc.
MMEN
Exchange: CNSX
Founded: 2010
CA$233,934,151
CA$131,448,292
620,100,697
Website: http://www.medmen.com
Address: MedMen Enterprises Inc.
10115 Jefferson Boulevard,
Culver City,
California, 90232,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX MMEN Class B Subordinate Voting Shares Canadian National Stock Exchange CA CAD 29. May 2018
OTCPK MMNF.F Class B Subordinate Voting Shares Pink Sheets LLC US USD 29. May 2018
DB 0JS Class B Subordinate Voting Shares Deutsche Boerse AG DE EUR 29. May 2018
BST 0JS Class B Subordinate Voting Shares Boerse-Stuttgart DE EUR 29. May 2018
Number of employees
Current staff
Staff numbers
1,000
MedMen Enterprises employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/02/22 03:20
End of day share price update: 2020/02/21 00:00
Last estimates confirmation: 2020/02/13
Last earnings filing: 2019/11/26
Last earnings reported: 2019/09/28
Last annual earnings reported: 2019/06/29


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.